Table 5. Literature review of cytoreductive surgery and perioperative intraperitoneal chemotherapy for malignant peritoneal mesothelioma (16).

Treatment center	Number of patients	Residual disease status	HIPEC technique	PIC agents	HIPEC duration (min)	HIPEC Temp (°C)	Mortality (%)	5-year OS (%)	Median survival (months)	Grade III/IV morbidity (%)
Multicenter, 2011 (60)	294	47% <2.5 mm	Variable	Variable	Variable	Variable	–	52	67	–
Milan, Italy, 2010 (61)	83	80% <2.5 mm	Closed	Cisplatin, MMC	90	42.5	2.4	50	44	28
Multicenter, 2009 (62)	401	46% <2.5 mm	Variable	Variable	Variable	Variable	2	47	53	31
New York, NY, 2008 (63)	27	1st surgery: 44% <5 mm; 2nd surgery: 48% <5 mm	Open	Cisplatin, doxorubicin, γINF, MMC	60	41	0	67 (3-year)	70	30
Washington, DC, 2007 (64)	62	37% <2.5 mm	Open	Cisplatin, doxorubicin. EPIC: paclitaxel	90	41.5	3	50	79	41
Lyon, France, 2006 (65)	15	73% <2.5 mm	Closed	Cisplatin, MMC	90	42	0	29	36	40
Milan, Italy, 2006 (66)	49	82% <2.5 mm	Closed	Cisplatin, doxorubicin, MMC	90	42.5	0	57	Not reached	27
NCI, Bethesda, MD, 2003 (67)	49	88% <1 cm; 33% <5 mm	Open	Cisplatin. EPIC: paclitaxel	90	41	0	59	92	25
Wake Forest, NC, 2001 (1)	12	60% <2.5 cm	Closed	MMC	120	42.5	8	33	34	–

Adapted from (16). HIPEC, hyperthermic intraperitoneal chemotherapy; MMC, mitomycin C; EPIC, early post-operative intraperitoneal chemotherapy.